Gorskyconomics: how J&J can make more from less
This article was originally published in Scrip
Six months in, and Johnson & Johnson's new CEO Alex Gorsky is on the road, introducing himself to the world. Speaking on 'Innovation and Beyond in Healthcare' at an open event at London School of Economics and Political Science yesterday, he was focused on the big picture of healthcare provision worldwide, and how to get the best despite increasingly restrictive resources.
You may also be interested in...
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
French phama pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.